肠道菌群在心血管疾病及治疗中的研究进展

Research progress on roles of gut microbiota in cardiovascular disease and treatment

心血管疾病(CVD)是一种严重危害人类健康的慢性疾病,位居全球患病率和死亡率首位。在人类肠道聚集了细菌、病毒等组成的群落,连同它们的基因组一起被称为肠道菌群。近年来,研究表明肠道菌群通过产生和释放氧化三甲胺、胆汁酸和短链脂肪酸等重要代谢物,影响宿主的各种代谢途径,在动脉粥样硬化、高血压、心肌梗死、心力衰竭、血脂异常等多种CVD中发挥重要作用。膳食干预、粪便移植、小分子微生物酶抑制疗法等基于肠道菌群的个体化治疗方案可能为CVD提供新的治疗策略。

Cardiovascular disease(CVD),a chronic disease endangering human health,remains the highest morbidity and mortality globally.The human gut is inhabited by communities of bacteria and viruses,along with their genome,are collectively known as the gut microbiota.Recent reserch suggests that gut microbiota affects various metabolic pathways in the host by producing and releasing important metabolites such as trimethylamine oxide,bile acids and short chain fatty acids,and play an important role in pathologies of CVD,such as atherosclerosis,hypertension,myocardial infarction,heart failure and dyslipidemia.Individual treatment based on gut microbiota,including diet intervention,fecal microbiota transplantation and small molecule antimicrobial enzyme therapeutics,may provide a potential novel strategy for therapeutics.